EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Deep Brain Stimulation for Focal or Segmental Craniocervical Dystonia in Patients Who Have Failed Botulinum Neurotoxin Therapy—A Narrative Review of the Literature

Thorsten M Odorfer iD, Jens Volkmann

Toxins · 09.10.2023 · 15 (10) · 606

DOI: 10.3390/toxins15100606 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxins, online erschienen am 09.10.2023. Verfasst von Thorsten M Odorfer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Würzburg, Josef-Schneider-Str. 11, 97080 Würzburg, Germany. Hauptthemen laut MEDLINE: Botulinum Toxins, Deep Brain Stimulation, Dystonic Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Open Access Publication Fund of the University of Wuerzburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

The first-line treatment for patients with focal or segmental dystonia with a craniocervical distribution is still the intramuscular injection of botulinum neurotoxin (BoNT). However, some patients experience primary or secondary treatment failure from this potential immunogenic therapy. Deep brain stimulation (DBS) may then be used as a backup strategy in this situation. (2)

Methods

Here, we reviewed the current study literature to answer a specific question regarding the efficacy and safety of the use of DBS, particularly for cervical dystonia (CD) and Meige syndrome (MS) in patients with documented treatment failure under BoNT. (3)

Results

There are only two studies with the highest level of evidence in this area. Despite this clear limitation, in the context of the narrowly defined research question of this paper, it is possible to report 161 patients with CD or MS who were included in studies that were able to show a statistically significant reduction in dystonic symptoms using DBS. Safety and tolerability data appeared adequate. However, much of the information is based on retrospective observations. (4)

Conclusions

The evidence base in this area is in need of further scientific investigation. Most importantly, more randomized, controlled and double-blind trials are needed, possibly including a head-to-head comparison of DBS and BoNT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum ToxinsDeep Brain StimulationDystonic DisordersHumansMeige SyndromeRandomized Controlled Trials as TopicRetrospective StudiesTorticollisTreatment Outcome

Stichwörter der Autor:innen

Meige syndromebotulinum neurotoxincervical dystoniadeep brain stimulationinternal globus pallidusmedication therapy failuresafety and tolerabilitysubthalamic nucleussymptom control

Substanzen

Botulinum Toxins

Autor:innen und Institutionen

  • Department of Neurology, University Hospital Würzburg, Josef-Schneider-Str. 11, 97080 Würzburg, Germany.

ORCID-Profile: Thorsten M Odorfer

Förderung

  • The Open Access Publication Fund of the University of Wuerzburg

Zitieren

APA

Odorfer, T. M., & Volkmann, J. (2023). Deep Brain Stimulation for Focal or Segmental Craniocervical Dystonia in Patients Who Have Failed Botulinum Neurotoxin Therapy—A Narrative Review of the Literature. Toxins, 15(10), 606. https://doi.org/10.3390/toxins15100606

Vancouver

Odorfer TM, Volkmann J. Deep Brain Stimulation for Focal or Segmental Craniocervical Dystonia in Patients Who Have Failed Botulinum Neurotoxin Therapy—A Narrative Review of the Literature. Toxins. 2023;15(10):606. doi:10.3390/toxins15100606

BibTeX
@article{Odorfer2023,
  author = {Odorfer, Thorsten M and Volkmann, Jens},
  title = {Deep Brain Stimulation for Focal or Segmental Craniocervical Dystonia in Patients Who Have Failed Botulinum Neurotoxin Therapy—A Narrative Review of the Literature},
  journal = {Toxins},
  year = {2023},
  volume = {15},
  number = {10},
  pages = {606},
  doi = {10.3390/toxins15100606}
}
Kostenlos starten →